Notification of Major Interest by Alto Invest to 4.15%

31st May 2016 - 2:07 pm

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 30 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming that it has increased its holding to 5,053,548 million Ordinary Shares in the capital of the Company. This represents 4.15% of ImmuPharma’s total voting rights, crossing above the 4% threshold.

Alto Invest is an independent asset management firm regulated by the French financial markets authority and is a specialised investor in European small and mid-cap companies.

Share this article

Leave a comment